GALT vs. ZYME, STOK, UPB, SION, ORIC, PHAR, SYRE, SPRY, PRAX, and QURE
Should you be buying Galectin Therapeutics stock or one of its competitors? The main competitors of Galectin Therapeutics include Zymeworks (ZYME), Stoke Therapeutics (STOK), Upstream Bio (UPB), Sionna Therapeutics (SION), Oric Pharmaceuticals (ORIC), Pharming Group (PHAR), Spyre Therapeutics (SYRE), ARS Pharmaceuticals (SPRY), Praxis Precision Medicines (PRAX), and uniQure (QURE). These companies are all part of the "pharmaceutical products" industry.
Galectin Therapeutics vs. Its Competitors
Galectin Therapeutics (NASDAQ:GALT) and Zymeworks (NYSE:ZYME) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, dividends, risk, profitability, institutional ownership, earnings, analyst recommendations and valuation.
Galectin Therapeutics currently has a consensus target price of $6.00, indicating a potential upside of 31.29%. Zymeworks has a consensus target price of $21.43, indicating a potential upside of 34.05%. Given Zymeworks' higher possible upside, analysts plainly believe Zymeworks is more favorable than Galectin Therapeutics.
Galectin Therapeutics has higher earnings, but lower revenue than Zymeworks. Zymeworks is trading at a lower price-to-earnings ratio than Galectin Therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, Galectin Therapeutics had 5 more articles in the media than Zymeworks. MarketBeat recorded 6 mentions for Galectin Therapeutics and 1 mentions for Zymeworks. Zymeworks' average media sentiment score of 1.83 beat Galectin Therapeutics' score of 0.62 indicating that Zymeworks is being referred to more favorably in the news media.
Galectin Therapeutics has a net margin of 0.00% compared to Zymeworks' net margin of -182.75%. Galectin Therapeutics' return on equity of 0.00% beat Zymeworks' return on equity.
Galectin Therapeutics has a beta of 0.86, suggesting that its share price is 14% less volatile than the S&P 500. Comparatively, Zymeworks has a beta of 1.27, suggesting that its share price is 27% more volatile than the S&P 500.
11.7% of Galectin Therapeutics shares are owned by institutional investors. Comparatively, 92.9% of Zymeworks shares are owned by institutional investors. 50.1% of Galectin Therapeutics shares are owned by insiders. Comparatively, 1.9% of Zymeworks shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Summary
Galectin Therapeutics and Zymeworks tied by winning 8 of the 16 factors compared between the two stocks.
Get Galectin Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for GALT and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding GALT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Galectin Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:GALT) was last updated on 9/17/2025 by MarketBeat.com Staff
Free GALT Stock Alerts